In addition, the negative regulator of PI3K/AKT, PTEN, has been reported to be a direct target of METTL3 in HCC [51] and chronic myelocytic leukemia (CML) [52]. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.